Objective To ascertain demographic and clinical features of parkinson disease (pD) associated with functional neurological features. Methods a standardised form was used to extract data from electronic records of 53 pD patients with associated functional neurological disorders (pD-FND) across eight movement disorders centres in the Usa, canada and europe. These subjects were matched for age, gender and disease duration to pD patients without functional features (pD-only). Logistic regression analysis was used to compare both groups after adjusting for clustering effect. results Functional symptoms preceded or co-occurred with pD onset in 34% of cases, nearly always in the most affected body side. compared with pD-only subjects, pD-FND were predominantly female (68%), had longer delay to pD diagnosis, greater prevalence of dyskinesia (42% vs 18%; p=0.023), worse depression and anxiety (p=0.033 and 0.025, respectively), higher levodopaequivalent daily dose (972±701 vs 741±559 mg; p=0.029) and lower motor severity (p=0.019). These patients also exhibited greater healthcare resource utilisation, higher use of [(123)I]Fp-cIT specT and were more likely to have had a pre-existing psychiatric disorder (p=0.008) and family history of pD (p=0.036). Conclusions a subtype of pD with functional neurological features is familial in one-fourth of cases and associated with more psychiatric than motor disability and greater use of diagnostic and healthcare resources than those without functional features. Functional manifestations may be prodromal to pD in one-third of patients.
InTrOduCTIOn
Parkinson disease (PD) and functional neurological disorders (FNDs) are considered distinct disorders with non-overlapping pathophysiological mechanisms. However, the coexistence of FND is well recognised in organic neurological disorders. Patients with 'functional overlay' are reported to have more anxiety and depressive symptoms. 1 Certain neurobiological features in organic disorders may explain a predisposition to developing comorbid FND. 2 Recently, FNDs have been reported to co-occur with PD and related neurodegenerative disorders. 3 4 Some features such as gastric symptoms, anxiety and pain are difficult to correctly classify as FND [3] [4] [5] and may instead represent non-motor features of PD. Nevertheless, in a series of 11 patients with PD and FND, 4 exhibited functional manifestations predating PD diagnosis. 6 Most of these functional symptoms led to significant disability and escalation of PD treatment, including requests for consideration of deep brain stimulation (DBS).
We sought to determine the clinical and demographic features associated with an increased prevalence of functional complications in PD (PD-FND), in particular motor lateralisation and dopaminergic medication usage. We hypothesised that these clinical features would differ from those of age-matched, gender-matched and disease duration-matched PD patients without FND (PD-only).
MeThOds
We conducted a multicentre case-control study involving nine movement disorder centres in the USA, Canada, the UK and Italy. Investigators used a standardised data collection sheet using deidentified clinical information extracted from electronic medical records.
study population and data collection
Standardised chart review collected demographic (age and gender) and clinical data for both patient groups. Investigators were asked to search electronic medical records of all patients with PD within their clinic for keywords or phrases such as 'psychogenic', 'functional', 'variable severity', 'deliberately effortful' or 'inconsistent with Parkinson disease'. In addition, investigators from each centre also were asked to consider additional patients whose symptoms were recalled as excessive or disproportionate to objective impairment to enhance the odds of finding additional subjects with comorbid functional symptoms who may have met inclusion criteria. Inclusion criteria for PD included the diagnosis of idiopathic PD according to UK Brain Bank criteria 7 at least 18 years of age and Hoehn & Yahr Stage I-IV in the ON state. 8 Patients with PD who had documentation of any (motor or non-motor) FND, meeting criteria for clinically definite FND according to Gupta and Lang criteria (for functional movement disorders (FMDs)), were included as PD-FND cases. 9 Comorbid functional symptoms such as nausea, cognitive symptoms, pain and fatigue, meeting criteria as Somatic Symptom Disorder in DSM-5, were also included. The available clinical scales taken during routine clinical practice included the motor subscale of the Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS-III) in the ON dopaminergic medication state, Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Parkinson's Disease Questionnaire-39 (PDQ), Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE). However, only standardised scales and objective data (gender, age, age of onset, treatment and their dosages, etc) were included. Non-motor functional symptoms were included if they met DSM-5 criteria for FND, which included (a) symptoms of altered voluntary motor or sensory function; (b) clinical findings that provided evidence of incompatibility between the symptom and PD or its treatment; (c) the symptom was not better explained by PD and (d) the symptom caused clinically significant distress or impairment in social, occupational or other important areas of functioning. 10 Other neurological and psychiatric comorbidities were also recorded if a formal diagnosis was documented. Data were entered and stored in a secure collection system, Research Electronic Data Capture. The most updated clinical data were retrieved, and data not available for each patient were omitted from the analysis.
Cases were only included if the PD-FND diagnosis was confirmed after full review of all chart notes and video documentation. In cases of uncertainty, the case was excluded. A second investigator at a different site reviewed all eligible cases, and both parties had to agree to allow inclusion. PD-FND cases (n=53) were individually matched for gender, age and disease duration (within 3 years) to PD-only controls within each originating centre. Matched PD-only controls were selected proportionally to the number of PD-FND at each centre. Controls were selected from a consecutive cohort based on the patients who fit match criteria that most recently visited the clinic. Data from these deidentified pairs were then submitted to the University of Cincinnati for collation into a single spreadsheet for data analysis.
FND was considered to have a rapid onset if symptoms fully appeared within a 6-month period and was considered static if they did not progress after documentation of the initial onset. Cognitive decline was measured using MMSE and MoCA scores and compared between groups. Healthcare utilisation data, including number of movement disorders office visits, hospitalisations, phone calls and messages, since joining the movement disorders clinic were collected. Data were available only for events within the providers' respective healthcare system. Year of symptom onset and clinical diagnosis for PD and FND were recorded. Neurological and psychiatric comorbidities and FND symptom onset were analysed in relation to timing of PD diagnosis. 6 Dosage of dopaminergic therapy, history of DBS and outcome of [(123)I]FP-CIT SPECT (DATscan) were also recorded, when available. Levodopa-equivalent daily dose (LEDD) was calculated according to the conversion table proposed by Tomlison et al. 11 PD and FND symptoms were categorised and analysed separately.
statistical analysis
Appropriate summary measures (mean and SD) were used for quantitative variables, and frequency and proportion for categorical variables. Clinical variables were compared between groups using logistic regression analysis after adjusting for clustering effect. Further, non-normal quantitative data were compared between two groups using non-parametric rank-sum test for clustered data. Robust variance was estimated to account for matching age, gender and disease duration. In the subgroup analysis, the prevalence of functional phenotype was estimated and reported along with 95% CI. All continuous variables were compared using unpaired t-test or Wilcoxon rank-sum test while Kruskal-Wallis test was used for comparing data between more than two groups. In addition, Fisher's exact test was used for comparing categorical data between groups. P values of <0.05 were considered significant. Correction for multiple comparisons was not conducted given the exploratory nature of the study. Spearman rank correlation analysis was explored for age, timing of diagnosis and delays in diagnosis with healthcare utilisation by groups. Sample size was computed based on two aims: (a) determine the prevalence of functional phenotype (such as tremor, dystonia, myoclonus, parkinsonism) among patients with PD-FND and (b) compare clinical scales (MDS-UPDRS) and characteristics (psychiatric disorders, and dyskinesia) with PD controls. A previous study estimated the prevalence of tremor (48.5%), dystonia (15.2%), myoclonus (15.2%) and parkinsonism (7.6%) among FMDs and compared disability and psychopathology with patients with PD. 12 We postulated that we would obtain similar distributions of functional phenotypes in patients with PD-FND with 20%-30% confidence width, depending on the prevalence. Based on this, at least 50 cases of PD-FND were required to produce a two-sided 95% CI with proposed width sizes. Further, this study reported moderate (0.55) to large effect sizes (0.80) for quality of life, psychiatric distress, anxiety, depression and somatisation. Based on this assuming a moderate effect size (0.6), a sample size of 64 (32 per group) was found to be sufficient to detect a significant change in MDS-UPDRS with 80% power and at 5% level of significance using a paired t-test/ clustered logistic regression. Thus, we proposed to include at least 50 patients per group which allowed detection of significant differences for moderate effect sizes for most of the clinical outcomes due to matched study design. All analyses were carried out using STATA V.13.
resulTs
We examined a total of 106 patients (72 women (68%)), including 53 PD-FND (age, 62±10 years; PD duration, 9±5 years) and 53 PD-only patients (63±10 years; duration, 9±5 years) (table 1). PD diagnosis was more likely to be confirmed by DATscan in the PD-FND group (58% vs 30%; P<0.001) than the PD-only group. Patients with PD-FND had a higher proportion of family history of PD (25% vs 8%; P=0.036) and higher frequency of psychiatric disorders, both before (67% vs 40%; P=0.008) and after onset of the first PD symptom (85% vs 72%; P=0.033).
Clinical features
Compared with PD-only, PD-FND was associated with higher BAI and BDI scores (34±8 vs 17±7 and 21±10 vs 14±8; P=0.033 and 0.025, respectively) (table 1) and higher total LEDD (972±701 mg vs 741±557 mg; P=0.029) (table 2). The PD-FND cohort had a greater prevalence of dyskinesia during motor evaluation (42% vs 18%; P=0.023) and lower MDS-UP-DRS-III scores (25±14 vs 30±11; P=0.019) (table 1). MoCA and MMSE scores were similar between the two groups.
Movement disorders Characteristics of the functional phenotype
In the PD-FND cohort, FND symptom onset antedated PD diagnosis by <3 years (n=5), 3-5 years (n=3), 6-10 years (n=4) or >10 years (n=2) in 14 patients (26%). FND occurred simultaneously to PD in 4 (8%), after in 30 (57%) and was unknown in 5 (9%). For cases whose FND symptoms antedated PD diagnosis, there was a longer delay reaching a diagnosis of PD compared with those whose FND symptoms began after PD diagnosis (3.5±2.4 vs 2.1±2.4 years; P=0.017) (table 3) .
The onset of functional symptoms was rapid in 55% of cases. Gait/balance impairment and tremor were most frequent, at about 40% each, and 60% of cases had at least two functional manifestations (figure 1). Violent dyskinesia/shaking spells and non-motor functional symptoms (subcategorised as: pain (n=8); cognitive decline (n=2); nausea (n=2); fatigue (n=1) and other (n=2)) were each present in 25%, as well as functional parkinsonism in 21%, dystonia in 15%, speech impairment in 11% and myoclonus in 6% of cases. Functional symptoms fluctuated with levodopa intake in 12 cases (23%) and did not in 16 (30%) (response unavailable in 25 cases (47%)). Of the patients whose functional symptoms entered remission (n=24), 71% had at least one relapse of functional symptoms over the course of a mean of 3.5 years of after-diagnosis data. The course of symptoms was static in 55% and progressive in 30% of cases (unknown in 15%). Overall, symptoms worsened in 7 (13%), improved in 12 (23%), resolved in 5 (9%) and did not change in 23 patients (43%) (unknown in 11%).
healthcare utilisation
Compared with PD-only, patients with PD-FND used more healthcare resources (table 4). Patients called their physician's office more (34±45 vs 17±23 calls; P=0.007) and had more hospitalisations (1.2±1.9 vs 0.9±2.6 visits; P=0.007). There were no significant between-group differences in the number of office visits or electronic messages captured. 
dIsCussIOn
We found that PD patients with functional features were on higher dopaminergic medication dosages, had more dyskinesia, exhibited greater depression and anxiety symptoms, and required more attention by clinicians than age-matched, gender-matched and disease duration-matched PD patients without functional complications. Importantly, functional manifestations antedated the diagnosis of PD in 26% and were noted at time the of PD diagnosis (confirmed by DATscan during an evaluation in patients with only suspected FND) in 8%, nearly always manifesting on the more affected PD side. Gait/balance impairment and tremor were the most common functional phenotypes in patients with PD-FND, with a prevalence of about 40% each. Incongruent ballistic dyskinesia (with descriptions from source documents ranging from 'severe shaking spells', to 'restless body syndrome', to 'arm flailing', to non-epileptic seizures), which may have initially been confused with levodopa-induced (dose-dependent) peak-dose or diphasic dyskinesia were described in 25% of the PD-FND cohort. While the study was not designed to address the prevalence of functional complications in PD, we calculated the prevalence of PD-FND among the patients presented at the University of Cincinnati corresponded to 1.4% of all active patients. More liberal inclusion criteria estimated the prevalence of functional symptoms in PD as high as 7.5%. 4 Nevertheless, the recognition of cases may be lower than actual as reflected by a longer delay to PD diagnosis and more frequent use of DATscan. In addition, seven (13%) of patients with PD-FND underwent DBS surgery, arguing that the disability of these patients, while disproportionally psychiatric over motor in nature, may force consideration 
Movement disorders
of advanced treatments at a higher rate than in the absence of functional manifestations, as recently reported in one patient. 13 In contrast to the left-sided predominance of motor symptoms (right hemispheric involvement) ascertained for patients with epileptic seizures complicating their course with non-epileptic seizures (psychogenic non-epileptic seizures (PNES)), 2 no differences on lateralisation of symptoms were demonstrated in our PD-FND cohort. Right-sided PD onset was more common across both groups but there was similar frequency of left-sided and right-sided onset of functional symptoms and these were more likely to appear in the more affected side. More intriguingly, while patients with both epileptic and PNES almost universally develop PNES after epilepsy, 2 14 functional features predated or co-occurred in a substantial proportion of patients with PD.
Recent data suggest a higher frequency of somatoform disorders, defined as conversion motor or sensory disorders, among patients with PD (7.5%) and dementia with Lewy bodies (18%) compared with patients with other neurodegenerative disorders, followed for up to 4 years, 4 as well as a more prevalent family history among patients with PD with functional complications compared with those without, which may suggest a genetic component for the PD-FND subtype. Higher somatisation scores, as recorded by the Symptom Checklist 90 Revised, have been reported in PD by women (70% vs 46%) with higher UPDRS scores (P<0.01). 15 The PD-FND cohort had lower UPDRS scores, possibly due to higher LEDD as the result of the initially unrecognised functional features, with the overall behaviour characterised as undertreatment. Alternatively, the high LEDD may have directly predisposed to FND (the study design precludes ascertaining the direction of causality). With regards to FND co-occurring or antedating PD in one-third of the PD-FND cohort, it is possible a selection bias could have occurred if patients with FND already were receiving care from a neurologist, making PD onset more easily recognised. On the other hand, other prodromal symptoms, such as depression and anxiety, could have influenced the onset of FND.
Although this is the largest study of PD-FND, our study has several limitations worth highlighting. Recall and selection biases, inherent to retrospective case-control studies, could have influenced enrolment despite the strict enrolment criteria and selection methods aimed to reduce these as much as possible. Data were retrospectively recorded from electronic medical records and, thus, systematic clinical interviews could not be structured to obtain data for each patient. Data on non-motor PD symptoms were not available for analysis as most sites did not employ a standardised instrument for these symptoms. Any data that were not available for each subject, including the number of phone calls, which were not regularly collected at European centres, were omitted from the analysis. Data for healthcare utilisation outside of the provider's healthcare system were also not available. As with the clinical scales, which varied in completion according to the submitting centre's standard practice, the reduced power was reflected in the P values, whose calculations are dependent on sample size. The number of patients analysed is provided in tables 1-4. Still, data based on low counts should be interpreted with caution. Additionally, laboratory-supported definite FND diagnosis was not available for most phenotypes beyond tremor and myoclonus, which may have underestimated PD-FND identification. Because of this shortcoming, and the lack of DATscans for most patients with PD, some subjects may have been miscategorised. In addition, we did not include patients with PD dementia, which may have increased the prevalence of FND cases given the higher reported prevalence of FND among patients with dementia with Lewy bodies compared with PD (18% vs 7.5%).
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